1 us investigator meeting dias-4, san diego, january 2011 pharmacovigilance & adverse event...
TRANSCRIPT
![Page 1: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/1.jpg)
1 US Investigator Meeting DIAS-4, San Diego, January 2011
Pharmacovigilance &Adverse Event Reporting
15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC
Medical Safety AdvisorGlobal Pharmacovigilance HQ
![Page 2: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/2.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 2
Agenda
Context What will you get from this session? Safety and Pharmacovigilance at Lundbeck Working in partnership
Getting it ‘right first time’ Definitions of Adverse Events and Serious Adverse Events Ensuring correct diagnosis From diagnosis to coding Identifying causality Using the study reporting tools
![Page 3: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/3.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 3
Voting pads
![Page 4: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/4.jpg)
4 US Investigator Meeting DIAS-4, San Diego, January 2011
Context
![Page 5: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/5.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 5
Your patients, our reputation
Why we are here: A new medicine that may help doctors and patients So far, so good, but this is still ‘something new’ Our first duty: the safety of trial participants You are our eyes and ears What we do will affect how this medicine benefits patients
![Page 6: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/6.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 6
60 minutes, to safeguard study participants
What you will get from this presentation:
How we will work togetherHow to save time and avoidreworkHow to reportHow to use the reporting toolsOpportunity to ask questions
![Page 7: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/7.jpg)
How many safety/ pharmacovigilance presentations have you been to?
7
Interactive question
15%
7%
25%
24%
28% 1. This is my first
2. A few
3. A lot
4. Far more than you can imagine
5. I could probably give this presentation myself
![Page 8: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/8.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 8
Please give us yourundivided attention
![Page 9: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/9.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 9
Pharmacovigilance: The science of safety
Understanding and preventing adverse events by:Monitoring and reporting the use of the drugDetecting and assessing any adverse effectsAssessing frequency, riskfactors, levels of riskAssessing risk versus benefit
![Page 10: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/10.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 10
Working together
First point: the patient comes first Partners in an investigative process Simplicity, accuracy and ‘right first
time’ Unclear or incomplete data will be
followed up Every report is followed up
appropriately
![Page 11: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/11.jpg)
11 US Investigator Meeting DIAS-4, San Diego, January 2011
Getting it‘right first time’
![Page 12: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/12.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 12
Adverse events
What is an Adverse Event? Untoward, or out of place, medical event during the clinical trial Patients included when they sign the consent form Events before first administration ARE included Does not need to be caused by the drug Unchanged pre-existing conditions are not AEs
![Page 13: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/13.jpg)
13
Interactive question
Which of the events shown should you report as an Adverse Event or Serious Adverse Event?
![Page 14: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/14.jpg)
14
Interactive question
80%
6%
15% 1. All 3 events should be reported
2. Only event number 3 should be reported
3. Events number 2 & 3 should be reported
Which of the events shown should you report as an Adverse Event or Serious Adverse Event?
![Page 15: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/15.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 15
Laboratory abnormalities can also indicate an Adverse EventIf the investigator believes they are clinically significantIf they lead to a change or discontinuation of treatmentIf they fulfil a seriousness criteriaIf they indicate a potential safety risk to the patient
Other things to note
![Page 16: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/16.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 16
Other things to note
Overdose At minimum, should be reported as an AE, stating whether intentional
or accidental If intentional, please add the reason Any symptoms resulting from the overdose should also be declared as
AEs Medication errors, drug abuse, drug interactions, quality issues with the
drug Medical or surgical procedures
The reason for the procedure should be reported as an AE
![Page 17: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/17.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 17
Other things to note
Pregnancy Should be reported as an AE within 24
hours using the ‘Pregnancy’ form and entered as an ‘AE’ in the eCRF
Any untoward event, such as spontaneous abortion, congenital anomaly or foetal death should be reported as a Serious Adverse Event
Report the outcome to Lundbeck, even if study has ended
![Page 18: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/18.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 18
What is a serious adverse event?
Death Life-threatening Results in persistent or permanent
disability or incapacity Results in birth defect/
congenital anomaly Requires
hospitalisation Medically important
![Page 19: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/19.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 19
Serious adverse events
All SAEs should be reported immediately, then tracked and updated until there is an outcome:
“Recovering”
“Recovered”
“Recovered with sequelae”
“Died”
“Did not recover”(for chronic conditions)
![Page 20: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/20.jpg)
20
Interactive question
Which of the following are serious adverse events?
1. Patient died after being stabbed with a knife
2. Patient broke leg and was admitted to hospital
3. Patient suffered anaphylactic shock
4. Patient gave birth to a healthy baby
5. Patient admitted for scheduled surgery to remove gall bladder
![Page 21: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/21.jpg)
21
Interactive question
9%
13%
21%
59%
Which of the following are serious adverse events?
1. Patient died after being stabbed with a knife
2. Patient broke leg and was admitted to hospital
3. Patient suffered anaphylactic shock
4. Patient gave birth to a healthy baby
5. Patient admitted for scheduled surgery to remove gall bladder
1. Events 1,2, 3 are SAEs
2. Events 1,2,3,5 are SAEs
3. Events 2,3 are SAEs
4. All 5 events are SAEs
Press one of the following options:
![Page 22: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/22.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 22
Reporting AEs and SAEs
Reports should include:Symptoms and/or diagnosisTheir intensityCause (if known)Causality assessmentAction takenOutcome
Be specific about cause and sequence: “Patient took an extra tablet because he forgot the previous dose”Patient presented with an arm fracture after falling over due to dizziness”
![Page 23: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/23.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 23
Symptoms and diagnosis
![Page 24: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/24.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 24
Symptoms and diagnosis
Ensure that cumulative symptoms are reported correctly:Together, chest pain, dyspnoea, diaphoresis and ECG changes can indicate a myocardial infarctionThe symptoms should be reported as AEs or SAEs as they occur but should be connected when the link becomes clear
![Page 25: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/25.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 25
Coding and why we do it
![Page 26: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/26.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 26
Causality
Is the AE or SAE linked to the study drug? Probably: There is a reasonable time relationship between the AE/SAE and
drug administration, or the AE/SAE recurs when the drug is taken again. Is unlikely to be caused by disease or other drugs.
Possibly: There is a suggested time relationship between the AE/SAE and drug administration, however, it could also be caused by disease or other drugs.
Not related: There is no time relationship between the AE/SAE and drug administration, or AE/SAE is caused by disease or other drugs.
![Page 27: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/27.jpg)
How many different CRF systems have you been trained in over the years?
27
Interactive question
9%
18%
22%
30%
21% 1. None
2. 1-3
3. 4 or 5
4. 6-10
5. More than 10
![Page 28: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/28.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 28
Recording using the eCRF
![Page 29: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/29.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 29
Recording using the eCRF
Our goals: Simple to use Necessary, but not excessive, data Clear purpose and subsequent outcomes
Your goals: Devote adequate time CRF completion as a priority task Consistent and, where appropriate, report diagnosis instead of signs and
symptoms
![Page 30: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/30.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 30
Sample entry: reporting a sequence of linked AEs
If possible combine signs and symptoms into a single diagnosis
Ensure the initially reported AEs (symptoms) are inactivated
Note whether the adverse event is serious
![Page 31: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/31.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 31
Sample entry: reporting an AE
![Page 32: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/32.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 32
Sample entry: reporting an AE
![Page 33: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/33.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 33
Sample entry: reporting an AE
![Page 34: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/34.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 34
Sample entry: reporting an AE
![Page 35: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/35.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 35
Sample entry: reporting a sequence of linked AEs
If possible combine signs and symptoms into a single diagnosis
Ensure the initially reported AEs (symptoms) are inactivated
Note whether the adverse event is serious
![Page 36: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/36.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 36
Sample entry: reporting a sequence of linked AEs
If possible combine signs and symptoms into a single diagnosis
Ensure the initially reported AEs (symptoms) are inactivated
Note whether the adverse event is serious
![Page 37: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/37.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 37
Sample entry: reporting a sequence of linked AEs
![Page 38: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/38.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 38
Sample entry: reporting a sequence of linked AEs
![Page 39: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/39.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 39
Sample entry: narrative reports
![Page 40: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/40.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 40
Sample entry: narrative reports
Narrative reports can be pasted into a free text field Give detail about the events leading to the AE Describe investigations and treatments Ensure the outcome is included
A good example:
On 12 October the patient was shovelling snow. The path was slippery and he fell and hit his head. He had not ingested alcohol and was not dizzy. He was hospitalised to be investigated (CT scan) and monitored for neurological injury. None was found and, on 14 October he was discharged with only a mild headache.
![Page 41: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/41.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 41
Sample entry: reporting a sequence of linked AEs
![Page 42: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/42.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 42
Sample entry: reporting a sequence of linked AEs
![Page 43: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/43.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 43
Back-up procedure
If it is not possible to use the eCRF, record SAEs on emergency worksheets
If necessary, continue to use these for follow-up assessments and reports
Send them to the contact details shown at the end
Update the eCRF at the earliest opportunity
![Page 44: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/44.jpg)
44 US Investigator Meeting DIAS-4, San Diego, January 2011
Summary
![Page 45: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/45.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 45
Summary
You are our eyes and ears -- we, and the study participants, are in your hands
Familiarise yourselves with the definitions of AEs and SAEs
Familiarise yourselves with the reporting tools
Getting it right, first time, will prevent follow-up contact and save you time
There is a support network to help answer any queries
![Page 46: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/46.jpg)
Has this session been:
46
Interactive question
18%
25%
34%
21%
3% 1. Unnecessary
2. Necessary but nothing new
3. Useful
4. Useful and engaging
5. So good, I’d like to sit through it again right now
![Page 47: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/47.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 47
For further information
All information in this presentation is summarised in the study protocol:
Section 9, pages 47-73 Ask your CRA or international/regional study manager Ask your Safety Advisor: [email protected]
Contact Details: For reporting, always use the eCRF Backup options: Fax +45 36 30 99 67 or email [email protected]
![Page 48: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/48.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 48
![Page 49: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/49.jpg)
49 US Investigator Meeting DIAS-4, San Diego, January 2011
Data Monitoring Committee(DMC)
![Page 50: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/50.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 50
DMC
The Data Monitoring Committee (DMC) is an independent expert advisory group
Combined DMC for 12402A (DIAS-3) study and 12649A (DIAS 4)
Purpose and functions: Monitoring the safety of patients Conduct a predefined interim futility analysis when
half of the patients have been evaluated in either one of the studies.
![Page 51: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/51.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 51
DMC
Members:3 external experts Chairman Deputy Chairman Third member
MeetingsThroughout the studies when a predefined number of patients have been enrolled and followed up for 90 days. First meeting: Feb 2010, 50 patients Second Meeting: 09 Feb 2011, 150 patients Thereafter for 250, 400, 550 and 700 patients
![Page 52: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/52.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 52
DMC members
Prof. Kennedy R. Lees, MDDMC Chair and Stroke SpecialistDepartment of Medicine Western InfirmaryGlasgow, UK
Dr Lawrence R. Wechsler, MDDeputy DMC Chair and Stroke SpecialistUniversity of Pittsburgh, Stroke InstitutePittsburgh, USA
Dr Michael Eliasziw, PhDDMC member and Biostatistics SpecialistDavLar BiostatsCalgary, Canada
Lundbeck personnel involved: Meredin Stoltenberg MD, PhD, DMScDMC secretaryH. Lundbeck A/S, Denmark
![Page 53: 1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical](https://reader036.vdocuments.net/reader036/viewer/2022081602/55143ef25503466d1a8b56ca/html5/thumbnails/53.jpg)
US Investigator Meeting DIAS-4, San Diego, January 2011 53